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Abstract
Background: Children hospitalised with severe anaemia in malaria endemic areas in Africa are at high risk of
readmission or death within 6 months post-discharge. Currently, no strategy specifically addresses this period. In
Malawi, 3 months of post-discharge malaria chemoprevention (PMC) with monthly treatment courses of artemether-
lumefantrine given at discharge and at 1 and 2 months prevented 30% of all-cause readmissions by 6 months post-
discharge. Another efficacy trial is needed before a policy of malaria chemoprevention can be considered for the post-
discharge management of severe anaemia in children under 5 years of age living in malaria endemic areas.
Objective: We aim to determine if 3 months of PMC with monthly 3-day treatment courses of dihydroartemisinin-
piperaquine is safe and superior to a single 3-day treatment course with artemether-lumefantrine provided as part of
standard in-hospital care in reducing all-cause readmissions and deaths (composite primary endpoint) by 6 months in
the post-discharge management of children less than 5 years of age admitted with severe anaemia of any or
undetermined cause.
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Methods/design: This is a multi-centre, two-arm, placebo-controlled, individually randomised trial in children
under 5 years of age recently discharged following management for severe anaemia. Children in both arms
will receive standard in-hospital care for severe anaemia and a 3-day course of artemether-lumefantrine at
discharge. At 2 weeks after discharge, surviving children will be randomised to receive either 3-day courses
of dihydroartemisinin-piperaquine at 2, 6 and 10 weeks or an identical placebo and followed for 26 weeks
through passive case detection. The trial will be conducted in hospitals in malaria endemic areas in Kenya
and Uganda. The study is designed to detect a 25% reduction in the incidence of all-cause readmissions or
death (composite primary outcome) from 1152 to 864 per 1000 child years (power 80%, α = 0.05) and requires
520 children per arm (1040 total children).
Results: Participant recruitment started in May 2016 and is ongoing.
Trial registration: ClinicalTrials.gov, NCT02671175. Registered on 28 January 2016.
Keywords: Malaria, Severe anaemia, Chemoprevention, Post-discharge, Readmission, Mortality,
Dihydroartemisinin-piperaquine, Protocol, Cost-effectiveness
Background
Severe anaemia, defined as haemoglobin (Hb) concentra-
tion level below 5.0 g/dL or haematocrit below 15.0%
[1], is a major public health problem in low and
middle-income countries. Severe anaemia is associated
with approximately one third of hospital admissions
among febrile children in sub-Saharan Africa, contribut-
ing substantially to paediatric morbidity and mortality,
especially in malaria endemic areas [2, 3]. Children
under 5 years of age are most vulnerable to the
long-term effects of severe anaemia, including decreased
cognitive performance and mental and motor develop-
ment [4]. Rates of in-hospital mortality due to severe an-
aemia ranging from 4 to 12% have been reported in
different epidemiological settings [5–7]. In addition,
these reports indicate a high post-discharge mortality
and morbidity, especially in the first 3 to 6 months. Lon-
gitudinal follow-up of children aged less than 5 years ad-
mitted with severe anaemia in Malawi showed that 8.2%
died by 6 months post-discharge and 5.9% were readmit-
ted with severe anaemia, compared to those without se-
vere anaemia, among whom 1.6% died and 0.5% were
readmitted [8, 9]. Similar high rates of post-discharge
mortality (10% by 8 weeks) were observed in malaria en-
demic areas of western Kenya [10] and in Uganda, where
12% died or were readmitted within 6 months [11].
Standard in-hospital treatment of severe anaemia in
many countries in sub-Saharan Africa consists of a blood
transfusion and parenteral artesunate for severe malaria
[12]. For severe malarial anaemia, this is completed with
a 3-day course of artemisinin-based combination therapy
(ACT), usually artemether-lumefantrine. Children are
often discharged with a short course of iron and folate,
typically with no further scheduled follow-up. Haemato-
logical recovery from malaria-associated anaemia takes
at least 6 weeks [13, 14]. However, many children in
these areas experience episodes of new or recrudescent
malaria infections after discharge. These infections
negate the initial rise in haemoglobin achieved by blood
transfusion, resulting in delayed haematological recov-
ery and potential rebound of severe anaemia and
death in some children [10, 15–17]. Furthermore, de-
layed haemolytic anaemia occurring 1 to 3 weeks
after artesunate treatment of falciparum malaria has
been reported in non-immune travellers [18, 19], al-
though more recent studies show this to be rare in
African children [20].
Malaria control strategies in endemic and epidemic-
prone areas include intermittent preventive therapy
(IPT). IPT is the administration of a full treatment
course using long-acting antimalarials at pre-defined
time intervals irrespective of a patient’s malaria status to
clear existing infections and to provide prolonged
prophylaxis against new infections [21]. The World
Health Organization (WHO) recommends IPT as a mal-
aria control strategy in malaria endemic areas for preg-
nant women (IPTp) [22, 23], infants (IPTi) [24] and for
children in areas with seasonal malaria transmission
(‘seasonal malaria chemoprevention’, or SMC) [25]. Cur-
rently, no control strategy specifically addresses the
high-risk post-discharge period for children previously
treated for severe anaemia in malaria endemic areas. In
Malawi, 3 months of malaria chemoprevention with
three full treatment courses of artemether-lumefantrine,
given in-hospital to children under 5 years of age admit-
ted with severe malarial anaemia, and at 1 and 2 months
post-discharge, prevented 31% of deaths or readmissions
by 6 months post-discharge, and 30% of all-cause read-
missions [17]. These results are consistent with earlier
findings from The Gambia which showed that, in chil-
dren with severe anaemia, chemoprevention targeted
during the malaria transmission season halved the rate
of clinical malaria and reduced all-cause hospital re-
admission by 78% in one trial and recurrence of severe
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anaemia by 78% in another [26, 27]. These data indicate
that malaria chemoprevention in the post-discharge
period may provide substantial health benefits.
We are conducting an efficacy trial in Kenya and
Uganda to determine the efficacy and safety of 3 months
of malaria chemoprevention post-discharge as a poten-
tially cost-effective strategy to reduce all-cause readmis-
sions and deaths in children admitted with severe
anaemia. We hypothesise that, by creating a prophylactic
time-window post-transfusion for malaria, more time is
assured for bone marrow recovery, resulting in a more
sustained haematological recovery post-discharge.
We refer to this strategy as post-discharge malaria che-
moprevention (PMC) to illustrate the similarities with
SMC rather than with IPT in pregnancy as it aims to pro-
vide complete, rather than intermittent prophylaxis.
Methods/design
Design overview
This will be a multi-centre, parallel group, two-arm,
placebo-controlled, individually randomised, superiority
trial with 1:1 allocation ratio comparing the safety and
efficacy of three courses of monthly PMC with
dihydroartemisinin-piperaquine (PMC-DP) or placebo
post-discharge provided in addition to the standard single
3-day treatment course with artemether-lumefantrine
given as part of routine in-hospital care (ClinicalTrials.gov,
NCT02671175; registered 28 January 2016). Randomisa-
tion to PMC-DP or placebo will occur at 2 weeks after en-
rolment, and PMC treatments will be administered at 2, 6
and 10 weeks. The primary outcome will be the number
of all-cause deaths or all-cause readmissions between 2
and 26 weeks after enrolment (composite outcome). The
study will be conducted in Uganda and Kenya, using ran-
domisation stratified by weight and study centre. The
study will include a total of 1040 children (520 per study
arm) less than 5 years of age who have been admitted for
severe anaemia and have successfully completed the
standard in-hospital treatment.
Primary objective
The primary objective is to determine if 3 months of
post-discharge malaria chemoprevention with monthly
3-day treatment courses of DP is superior to the single
3-day treatment course with artemether-lumefantrine
provided as part of standard in-hospital care in reducing
all-cause readmissions and deaths by 6 months in the
post-discharge management of children less than 5 years
of age admitted with severe anaemia.
Secondary objectives
The secondary objectives include the determination of
the safety of three courses of monthly DP and the
cost-effectiveness of PMC-DP compared to the current
standard of care.
Design considerations
Rationale for choice of DP for PMC
Optimal antimalarial prophylaxis with maximum com-
pliance would be provided by a regimen that is long act-
ing so that administration is not required more
frequently than monthly. Sulphadoxine, mefloquine and
DP have sufficiently long half-lives to be considered [28].
However, there is high-level resistance to sulphadoxine
in many parts of east and southern Africa, precluding its
use for this purpose in these malaria endemic areas [29].
Both amodiaquine [30] and mefloquine are poorly toler-
ated, which is an important consideration when provid-
ing drugs for malaria prevention to recipients with few
or no symptoms [31, 32]. DP is very effective, well toler-
ated and provides 4 to 5 weeks of post-treatment prophy-
laxis. It is therefore currently the drug of choice for use
for evaluation as part of IPT and malaria chemoprevention
in areas with high-grade parasite resistance to sulphadox-
ine [33–38]. Furthermore, recent studies show that
artemether-lumefantrine and DP exert inverse selective
pressure on Plasmodium falciparum drug sensitivity [39],
suggesting that DP may be a good choice for chemopre-
vention in areas where artemether-lumefantrine is the
first-line drug of choice for case management.
Why in this study population?
The primary study population involves children with se-
vere anaemia, rather than only children with severe mal-
arial anaemia, which was the study population in the
previous trial in Malawi [17]. This is based on observa-
tional studies in Malawi, Uganda and western Kenya
showing that children admitted with severe anaemia ap-
pear to be at increased risk of readmission and death re-
gardless of whether they had evidence of malaria
infection at the time of admission or not (Desai et al.,
unpublished observations; Richard Opoko, unpublished
observations) [17]. Second, reliable diagnosis of the pres-
ence of malaria is difficult, and the differentiation be-
tween severe anaemia and severe malarial anaemia is not
always feasible, as it is common practice in many hospi-
tals in sub-Saharan Africa to start parenteral treatment
with antimalarials before the laboratory diagnosis of
malaria is available. Furthermore, the interpretation of
malaria diagnostic tests on admission may be compli-
cated in children who received antimalarial treatment
just prior to admission [40].
Efficacy and effectiveness of delivery mechanisms
This current study is an efficacy trial, and each treat-
ment course will be provided by study staff directly. The
first dose of each course will be observed, and where
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feasible, doses on days 2 and 3 will also be given under
supervision, or compliance verified by home visits or
contacting caretakers by mobile phone. A separate trial,
focusing on the effectiveness of different delivery mecha-
nisms, is being conducted by our consortium members
in Malawi (NCT02721420).
Why this composite primary outcome?
Use of clinical malaria as primary outcome would re-
quire a smaller study; however, the composite outcome
is used because it is more likely to drive policy. We use
a composite outcome rather than a single severe out-
come, such as death, to keep sample size requirements
manageable.
Rationale for assessment by 6 months after enrolment
The period 2–26 weeks instead of 0–26 weeks is used
for the primary efficacy analysis because children will
not be randomised until 2 weeks after enrolment. Prior
to 2 weeks, all children, including those in the placebo
arm, will receive a 3-day course of artemether-lumefan-
trine as part of standard in-hospital care, which will be
started before discharge and completed at home
after discharge. The duration of post-treatment
prophylaxis in our previous trial with artemether-
lumefantrine is about 2 to 3 weeks [17], and we
therefore do not anticipate any differential effect be-
tween the arms until children receive their first
study-specific intervention upon randomisation. The
protective drug levels have waned in many children
by 14 weeks (i.e. about 4 weeks after the last PMC
course of DP), but we follow the children for a total
of 26 weeks to capture any potential prolonged ben-
efits or rebound effects.
Study settings
The study will be conducted in hospitals in Kenya and
Uganda located in areas with moderate to intense mal-
aria transmission [15, 16]. The annual entomological in-
oculation rates vary widely. In western Kenya they range
from 31.1 to 108.6 infective bites/person/year [41, 42] in
areas around Kisumu and Siaya respectively, while in
Uganda they range from 2.8 to 4 infective bites/person/
year [43, 44] in areas around Jinja and Mubende respect-
ively. In western Kenya, we will recruit participants from
hospitals located in areas around Lake Victoria with
well-documented malaria transmission intensity, in-
cluding the Jaramogi Oginga Odinga Teaching & Refer-
ral Hospital (JOOTRH) and Siaya, Kisumu, Homa Bay
and Migori County referral hospitals. In Uganda, we
will recruit from Jinja, Hoima, Masaka and Mubende
regional referral hospitals as well as Kamuli Mission
Hospital (Fig. 1).
Inclusion and exclusion criteria
The inclusion and exclusion criteria for pre-study
screening, enrolment and for randomisation 2 weeks
later are described in the following sections.
Eligibility criteria
Eligibility criteria for pre-study screening
The inclusion criteria for enrolment into the pre-
study screening period are as follows:
1. Haemoglobin < 5.0 g/dL or packed cell volume
< 15%, or requirement for blood transfusion for
other clinical reasons on or during admission to
the hospital
2. Aged less than 59.5 months
3. Bodyweight ≥ 5 kg
4. Resident in catchment area
The exclusion criteria for enrolment into the pre-
study screening period are the following:
1. Recognised specific other cause of severe anaemia,
e.g. trauma, haematological malignancy, known
bleeding disorder
2. Known sickle cell disease
3. Child will reside for more than 25% of the
6 months study period (i.e. 6 weeks or more)
outside of catchment area
Eligibility criteria for enrolment into study
The inclusion criteria for enrolment are as follows:
1. Fulfilled the pre-study screening eligibility criteria
2. Aged less than 59.5 months
3. Clinically stable, able to take oral medication
4. Subject completed blood transfusion(s) or became
clinically stable without transfusion
5. Able to feed (for breastfeeding children) or eat (for
older children)
6. Provision of informed consent by parent or
guardian
The exclusion criteria for enrolment are the following:
1. Previous enrolment in the present study
2. Known hypersensitivity to study drug
3. Use or known need at the time of enrolment for
concomitant prohibited medication including drugs
known to prolong the QTc interval during the 14-
week PMC treatment period (Additional file 1,
section 8.5.7, page 34)
4. Ongoing or planned participation in another clinical
trial involving ongoing or scheduled treatment with
prohibited medicinal products or active follow-up
during the study
Kwambai et al. Trials          (2018) 19:610 Page 4 of 12
5. A known need for scheduled surgery during the
subsequent course of the study
6. Anticipated non-compliance with the follow-up
schedule
7. Known heart conditions, or family history of
congenital prolongation of the QTc interval
Eligibility criteria for randomisation into study (at 2 weeks
post-discharge)
The inclusion criteria for randomisation are as follows:
1. Fulfilled enrolment eligibility criteria and was
enrolled during recent admission
2. Aged < 60 months
3. Still clinically stable, able to take oral medication,
able to feed (for breastfeeding children) or eat (for
older children) and able to sit unaided (for older
children who were already able to do so prior to
hospitalisation)
The exclusion criteria for randomisation are the
following
1. Used DP since enrolment
2. Use or known need at the time of randomisation
for concomitant prohibited medication (Additional
file 1, section 8.5.7, page 34).
3. Enrolled, or known agreement to enrol into another
clinical trial involving ongoing or scheduled treatment
with medicinal products during the study.
4. Withdrawal of consent since enrolment
Interventions
Trial medication and interventions
Children will be randomised to one of the two treatment
groups: DP or placebo. Children in both arms will
receive standard in-hospital care and, at discharge (en-
rolment) a 3-day course of artemether-lumefantrine re-
gardless of whether they were admitted with severe
malarial anaemia or severe anaemia without evidence of
malaria.
Artemether-lumefantrine The study will use a Good
manufacturing practices (GMP) formulation of
artemether-lumefantrine (Coartem®, Novartis Pharma-
ceuticals). The recommended treatment is a six-dose
regimen over a 3-day period with dosing per bodyweight
Fig. 1 Map of study setting in Kenya and Uganda. Study sites in both western Kenya and Uganda are in the lake endemic region. These are large
referral hospitals in the region with adequate diagnostic and treatment capacities for malaria and other conditions
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following WHO dosing recommendations as provided
for in the latest WHO malaria treatment guidelines [12]
(see Additional file 1: Table S3 on page 29).
Dihydroartemisinin-piperaquine The study will use
the Eurartesim® brand of DP from Alfasigma (formerly
Sigma Tau), Italy, a co-formulated tablet containing
40 mg dihydroartemisinin and 320 mg piperaquine
phosphate or as 20/160 (paediatric formulation). Dosing
will be per bodyweight according to the schedule recom-
mended by the current WHO guidelines (Additional file
1: Table S4 on page 30).
Placebo DP Placebos for DP will be manufactured by
Alfasigma, Italy. The dosage regimen for DP-placebo will
be identical in number of tablets per day and timing of
the dose to that of the active DP product. The drug ad-
ministration procedures will also be identical to that for
the active drugs.
Other medication
Standard in-hospital and post-discharge care Except
for the full 3-day course of artemether-lumefantrine, all
care provided prior to and following enrolment of the
participants in the study (at convalescence) will be ac-
cording to local (hospital) or national guidelines and
therefore not subject to this study. Treatment for mal-
aria in both Kenya and Uganda conforms with the
current WHO malaria treatment guidelines [12], which
include artemether-lumefantrine as first-line treatment
for uncomplicated malaria and parenteral artesunate for
severe malaria. Details of non-study-specific care pro-
vided by the hospital staff will be recorded.
Iron and folate supplementation All children will
receive 28 days of iron and folate supplementation at
2 weeks post-discharge as part of routine care for
severe anaemia. A standardised prophylactic dose of
iron supplementation (about 2 mg/kg) will be given
as monotherapy or as part of the fixed-dose formula-
tion with folic acid (see Additional file 1, section
8.5.2.7, page 31).
Outcomes
The primary and secondary efficacy outcomes are
discussed in the following sections.
Primary efficacy outcome
The primary efficacy outcome is the number of all-cause
deaths or all-cause readmissions between 2 and 26 weeks
after enrolment (composite outcome).
Key secondary efficacy outcomes
1. Readmission due to severe malaria (defined as
any treatment with parenteral quinine or
artesunate, or presence of severe anaemia and
treatment with oral antimalarials) by 26 weeks
from randomisation
2. Readmissions due to severe anaemia (defined as Hb
< 5 g/dL or packed cell volume < 15% or
requirement for blood transfusion based on other
clinical indication) by 26 weeks from randomisation
3. Readmission due to severe malarial anaemia (severe
anaemia plus parenteral or oral antimalarial treatment)
by 26 weeks from randomisation
4. Readmission due to severe anaemia or severe
malaria (composite outcome) by 26 weeks from
randomisation
5. All-cause mortality by 26 weeks from
randomisation
6. All-cause hospital readmission by 26 weeks from
randomisation
7. Clinic visits because of smear- or malaria rapid
diagnostic test (RDT)-confirmed non-severe malaria
by 26 weeks from randomisation
Other secondary efficacy outcomes
1. Readmission due to severe malaria-specific anaemia
(severe anaemia plus parenteral or oral antimalarial
treatment and parasite density > 5000/μL) by
26 weeks from randomisation
2. Readmission due to severe disease other than severe
anaemia and severe malaria by 26 weeks from
randomisation
3. Non-severe all-cause sick-child clinic visits by
26 weeks from randomisation
4. Non-malaria sick-child clinic visits by 26 weeks
from randomisation
5. Malaria infection at 26 weeks
6. Hb at 26 weeks
7. Any anaemia (Hb < 11 g/dL), mild anaemia (Hb
8.0–10.99 g/dL), moderate anaemia (Hb 5.0–7.99
g/dL) and severe anaemia (Hb < 5 g/dL) at 26 weeks
8. Weight-for-age, height-for-age and height-for-
weight Z-scores (standard deviation [SD] scores of
reference population) at 26 weeks
Tolerability and safety outcomes
1. Serious adverse events, excluding primary and
secondary efficacy outcomes, by 26 weeks from
randomisation
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2. Serious adverse events within 7 days after the start
of each course of PMC, excluding primary and
secondary efficacy outcomes
3. Adverse events by 26 weeks from randomisation
4. Adverse events within 7 days after the start of each
course of PMC
5. QTc prolongation measured by electrocardiogram
(ECG) 4–6 h after third dose of each course (in a
subset of patients)
Participant timeline
Overview of study phases and scheduled visits
The study timelines consist of an in-patient pre-study
screening period while the patient is acutely ill (visit
1), followed by a screening, consent and enrolment
visit (visit 2). During the convalescence phase in the
hospital, patients receive artemether-lumefantrine
(visit 3) prior to discharge. The patient returns to the
study clinic 14 days later (visit 4) for randomisation.
Home treatment visits are made at 6 (visit 5) and 10
(visit 6) weeks. The PMC period starts at 2 weeks
and ends at 14 weeks, but participants receive passive
follow-up for an additional 12 weeks and are then
seen at 26 weeks (visit 7) for an end-of-study
assessment (see Additional file 2, Fig. 2 and
Additional file 1, section 8.7, pages 37 to 40).
Unscheduled visits (passive follow-up)
A passive surveillance system is in place to monitor
intercurrent illnesses during the observation period.
Parents are instructed to bring their child to the
study clinic for any suspected illness. Blood samples
for Hb, malaria diagnosis (RDT and smear) and filter
paper dry blood spot (DBS) for parasite genetics are
obtained. Verbal autopsy is conducted for children
who die at home during the follow-up period.
Adverse events and vital status are assessed during all
scheduled or unscheduled visits.
Sample size
Original sample size
The initial estimate of the required sample size was 2212
children (1106 per arm) across both countries pooled.
This estimate was designed to detect a 30% reduction in
the incidence rate of the composite primary outcome
(death or all-cause readmission) from 469 per 1000 child
years in the control arm to 328 per 1000 child years in
the intervention arm (power 90%, α = 0.05), which
allowed for one interim analysis and 15.7% loss to
follow-up. For these estimations, we assumed an average
pooled event rate of 399 per 1000 child years across the
two arms, with 328 and 469 events per 1000 child years
in the intervention and control arms respectively (Rate
Ratio (RR) = 0.70). We based this assumption on
observations in western Kenya (Desai et al., unpublished)
and Malawi [17]. However, the observed event rate,
pooled across both arms, during the first year of the
study was 1120/1000 child years, which is almost three
times higher than the assumed event rates. The higher
rate is consistent with the recently published observa-
tions in Uganda [11]. Furthermore, the observed rate of
loss to follow-up in the first 533 participants recruited
and followed up for 6 months was 7% rather than the as-
sumed 15%.
Sample size re-estimation
Following recommendations from the Data Monitoring
and Ethics Committee (DMEC) and the Trial Steering
Committee (TSC), a blinded interim sample size
re-estimation was conducted to take into account the
lower than expected rate of loss to follow-up and the
higher than expected pooled incidence rate of the com-
posite primary endpoint (death or all-cause readmis-
sion). This was favoured over an interim analysis,
because the available funding did not allow an extension
of the recruitment period, even if the results of any in-
terim analysis had suggested that this would be required.
The revised sample size calculations show that a total
sample size of 1040 children (520 per arm) is required to
detect a 25% reduction in the incidence of the composite
primary outcome from 1152 per 1000 child years (530
events per 1000 children) in the control arm to 864 per
1000 child years (398 per 1000 children) in the interven-
tion arm (power 80%, α = 0.05), allowing for 10% loss to
follow-up. The same sample size also provides 90%
power to detect a 28.7% reduction in the primary end-
point from 1152 to 822 events per 1000 child years.
Assignment of interventions
Allocation
Eligible children are randomly assigned (1:1) to either
PMC-DP or placebo by a computer-generated randomisa-
tion schedule stratified by weight (per DP dosing sched-
ule) and study site using permuted blocks of random sizes
(see Additional file 1: page 30, Table S4) [12]. Recruitment
is ‘competitive’ between the sites in the trial.
Blinding
The study is double-blinded to both participants/care-
takers and study staff. Allocation concealment is
achieved by the use of sealed opaque envelopes, with
each envelope containing three other small envelopes
(one for each PMC course). The envelopes containing
active DP or placebo look identical, and the appearance
and consistency of the tablets are also identical.
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Laboratory procedures
Hb is measured using HemoCue 201 (HemoCue,
Angelholm, Sweden) photometers. Thick and thin blood
films for parasite counts are obtained and examined. The
films are read by two independent microscopists by count-
ing any malaria parasites against 200 high-power fields be-
fore a slide is declared negative [45]. Point-of-care malaria
diagnosis will be conducted using the First Response®
Malaria Ag. pLDH/HRP2 Combo Card Test (Premier
Medical Corporation, Mumbai, India).
Statistical methods
A detailed study statistical analytical plan for the final
analysis that will supersede the study protocol will be
developed during the study before the unblinding of
data.
Fig. 2 Study Design and Schedule of Assessment (Spirit figure)
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Analysis populations
The intention-to-treat (ITT) population is defined as all
randomised subjects allocated to one of the two treat-
ment arms and will be analysed in the group to which
they were randomised, regardless of the type (placebo or
active PMC) or number of courses received. The
per-protocol (PP) population is a subset of the ITT
population, excluding participants with major protocol
deviations.
Missing data
Every effort is being made to minimise the amount of
missing data in the trial, and whenever possible, infor-
mation on the reason for missing data is obtained. No
adjustments will be made for missing outcome data, but
missing data may be imputed for covariates.
Assessment of efficacy
Primary analysis will be by ITT and will include all pri-
mary endpoint events (i.e. first and repeat events). The
follow-up time will be measured as the time in days
from the date of randomisation to the end of follow-up
(around 26 weeks), death or drop-out. The incidence
rate will be calculated per arm and the incidence rate ra-
tio (IRR, PMC to placebo) and 95% confidence interval
(CI)estimated using Poisson regression models with
treatment (as randomised) as the only covariate. The re-
sults will also be expressed as the relative rate reduction
(RRR) (95% CI).
Sub-group analysis
We will use stratified analysis to assess to what extent the
effect of the intervention on the primary outcome is influ-
enced by country, demographic parameters (e.g. age, eth-
nicity and socio-economic status), clinical parameters,
malaria transmission variables (malaria transmission in-
tensity, residence (urban/rural), season, insecticide-treated
nets use, site), time of assessment and potential interven-
tion modifiers. Because we did not power the study for
sub-group analyses, we will interpret the results of the
sub-group analysis cautiously. No adjustment will be
made for multiple comparisons.
Sensitivity analyses
A number of sensitivity analyses will be conducted to as-
sess the robustness of the primary endpoint analysis.
These include analysis of the PP subject population and
a covariate adjusted analysis. Other regression models
will also be explored. Additional post hoc analyses may
also be conducted if deemed appropriate. In addition, we
will compare the results of the covariate-adjusted ana-
lyses with and without imputation for missing values for
covariate values at baseline.
Analysis of adverse events
Adverse events and serious adverse events are moni-
tored, managed and recorded during the study. They will
be recorded and tabulated for each treatment arm, over-
all, and per body system. Treatment emergent adverse
events are defined as adverse events that had an onset
day on or after the day of the first dose of study medica-
tion. No formal statistical testing will be undertaken. En-
rolled children who are clinically unstable 2 weeks
post-discharge (i.e. at the time eligibility is assessed for
randomisation) and/or have rebound severe anaemia are
re-admitted and become eligible for randomisation if
they fulfil the entry criteria 2 weeks after the subsequent
discharge.
Procedures for assessing efficacy and safety parameters
Primary efficacy outcome
All-cause mortality All-cause mortality will be assessed
during visits 4 (2 weeks), 5 (6 weeks) and 6 (10 weeks)
and at 18 weeks (by phone) and during the end-of-study
assessment at 26 weeks.
All-cause and disease-specific readmissions These
readmissions will be assessed through passive case de-
tection as well as a questionnaire administered during
visits 4–7 at 2, 6, 10 and 26 weeks and during unsched-
uled sick visits. Details of admissions and treatment that
the participants received are recorded including malaria
diagnostic test results and use of antimalarials to allow
for differentiation between malaria, severe anaemia and
other syndromes.
Secondary efficacy outcomes
Secondary efficacy outcomes include all-cause and
malaria-specific clinic visits. They will be assessed
through passive case detection as well as questionnaires
administered during visits 4–7 at 2, 6, 10 and 26 weeks
and during unscheduled sick visits. Details of clinic visits
are recorded including malaria diagnosis results to allow
for differentiation between malaria and non-malaria
clinic visits.
Adverse events
We will adhere to the International Conference on
Harmonisation (ICH) good clinical practice (GCP)
principles in recording, reporting and managing ad-
verse events and serious adverse events for all partici-
pants in both arms (see Additional file 1: page 51,
section 9.6.2).
Cardiac monitoring sub-study
The main safety concern with DP is its dose-dependent
QTc prolongation induced by the piperaquine
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component. Transient QTc prolongation has been con-
firmed in clinical trials, but there are no data suggesting
that the treatment is associated with clinically significant
arrhythmias [38, 46, 47]. A trial in Uganda among chil-
dren 6–24 months old included monthly DP for up to
18 monthly courses. A detailed sub-study of the effect of
DP on cardiac repolarisation was conducted in 26 chil-
dren and concluded that DP is not associated with a
trend toward increasing QTc prolongation with increas-
ing number of DP courses [38]. This type of safety data
is limited, and we will therefore conduct a nested cardiac
monitoring sub-study at Jinja Regional Referral Hospital
in Uganda among 66 children who will be selected
through convenience sampling. Separate written informed
consent will be sought for inclusion in this sub-study.
Approximately half of these children are expected to have
received PMC with DP. The primary objective is to deter-
mine whether transient QTc prolongation increases in
magnitude with subsequent courses of DP. Children en-
rolled in the sub-study will have an ECG taken prior to
the first dose of each course and again 4–6 h after taking
the third dose of each course of DP (anticipated maximum
drug concentration).
Discussion
Severe anaemia and severe malaria constitute a major
public health problem in malaria endemic areas of
Africa. Evidence suggests that a major, potentially pre-
ventable, component of the burden occurs after
discharge and that a proactive approach is needed. Cur-
rently, no strategy specifically addresses this high-risk
post-discharge period. This study seeks to determine the
efficacy, safety and cost-effectiveness of 3 months of
malaria chemoprevention post-discharge as an innova-
tive strategy to reduce all-cause readmissions and deaths
among children admitted with severe anaemia in malaria
endemic areas. The study settings in Kenya and Uganda
are representative of the main epidemiological settings
appropriate for this intervention. Members from our
consortium, under the leadership of the College of
Medicine in Malawi, are concurrently conducting a trial
in Malawi, under a separate protocol, on potential
delivery mechanisms and health services research to de-
termine the uptake, effectiveness, acceptability and feasi-
bility of different mechanisms for delivering PMC
(ClinicalTrials.gov: NCT02721420). This strategy builds
on existing approaches used for seasonal malaria chemo-
prevention in west Africa and experience with IPT in
pregnant women and infants [48, 49]. Should PMC
prove to be effective, cost-effective and feasible, it may
be a promising strategy to reduce all-cause readmissions
and deaths in children admitted with severe anaemia in
malaria endemic areas of Africa.
Trial status
Recruitment started in May 2016 and is ongoing.
Unblinding and analysis will begin after recruitment and
follow-up are completed and the database has been
completed, cleaned and locked.
Additional files
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